Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
101.40    -1.80 (-1.74%)
Bid:
101.40
Ask:
102.20
Spread: 0.80 (0.789%)
Market Cap: £166.24m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Update

15 May 2008 07:00

RNS Number : 4877U
Yule Catto & Co PLC
15 May 2008
 



Yule Catto & Co plc 

AGM Statement and Trading Update

At today's Annual General Meeting of Yule Catto & Co plc to be held at 12.00 noon at Saddlers' Hall, 40 Gutter Lane, London EC2V 6BR, Anthony Richmond-Watson, Chairman, will make the following statement, which comprises Yule Catto's Interim Management Statement for the period from 1 January 2008 to date.

"2007 was a good year for the Group. We made steady progress across all of our divisions in both our operational performance and strategic plans to develop the Group for the future. This showed through in the financial results.

"The Polymers business had another good year of growth in volumes and profit. Our strategy in Polymers remains focused on geographical expansion around our existing business hubs and developing market sectors where our product technology and manufacturing capabilities give us real competitive advantage. We are investing heavily in additional Nitrile capacity in Malaysia to take full advantage of the continued growth in this product and the Asian region.

"Our Pharma business continued to grow the range of generic and ethical products that it plans to manufacture by registering further drug master files in the year. As we had previously indicated Pharma earnings declined, in part due to the phasing of orders in the second half of the year. We announced plans to exit our Italian site to improve the operational cost base and the productivity of the business. This exit is proceeding to plan.

"Impact Chemicals has had a challenging year, but has delivered significant improvement. We are clearly seeing the benefits of our strategy to raise the performance of these businesses through restructuring and focussing on market segments offering better margins and growth.

"Overall, underlying Group profit before taxation increased some 10% to £34.5 million, and earnings per share by 18% to 17.3 pence per share.

"This has been a year in which much has been achieved. On behalf of the directors and shareholders, I would like to thank all our employees everywhere for their commitment and contribution towards the company's success.

Management Changes

"Alan Maddy, Chief Executive of the Polymer Division, will be retiring in August this year after 38 years with the Group. He is replaced by Derick Whyte, who was previously CEO of the Impact Division. Adrian Whitfield has assumed direct management control of the Impact businesses.

Board Changes

"David Blackwood joined the Group and the Board as Finance Director in October last year. Sandy Dobbie and Jez Maiden were appointed independent non-executive directors in August; their appointments arise out of our regular review of the board's composition. In the coming year we expect to address such issues further.

As far as my position as Chairman is concerned, I have decided that now is an appropriate time for the Board to initiate a process to appoint my successor.

"Messrs. Blackwood, Dobbie and Maiden seek election today having been appointed since the 2007 AGM. Dato' Seri Lee Oi Hian, Dato' Lee Hau Hian, Alex Catto and myself are also standing for re-election at today's meeting

Interim Management Statement

"2008 has started positively, with our un-audited management accounts showing revenues and profits in-line with our expectations and ahead of last year.

"Polymer Chemicals made solid start to the year, ahead on sales and profit, supported by the expanded nitrile capacity in Malaysia, where we remain on track to further expand nitrile capacity by approximately 60during the second half of the year.

"Pharma Chemicals experienced a very strong first half in 2007 based in the main on customer order phasing. Profit for the first quarter of this year is consequently below last year, but the results are in line with our expectations.

"The results for Impact Chemicals are ahead of last year as expected, benefitting from the restructuring programme. We have implemented further restructuring at William Blythe in the first quarter, and results there should further improve through the rest of the year.

"Overall the year has started well, though we see general signs of economic weakness around the world. We remain focused on delivering value from the Impact portfolio and improving the Pharma business through the Italian site restructuring programme. The Polymers business has made a solid start to the year, and should show further improvement again this year. Overall, despite the economic concerns we remain confident that 2008 will be a year of further improvement for the Group." 

15 May 2008

ENQUIRIES:

YULE CATTO 

Tel: 01279 442791

Adrian Whitfield, Chief Executive 

David Blackwood, Finance Director 

 

COLLEGE HILL 

Tel: 020 7457 2020 

Gareth David

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAIMFTMMABBIP
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.